RxDoctor Payments Data

Lauren Williams Bryant

Nurse Practitioner · Villa Rica, GANPI 1407550981

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 164 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$598
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$483
  • Johnson & Johnson$446
  • Phathom Pharmaceuticals, Inc.$351
  • Sanofi$324
  • Ardelyx, Inc.$187
  • plus $990 from 12 others

What the payments were for

  • Food & beverage$3,18794%
  • Education$1926%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$29,478
Medicare patients
246
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide83$63,842
ZenpepLipase/Protease/Amylase13$52,272
CreonLipase/Protease/Amylase12$33,075
VoqueznaVonoprazan Fumarate11$9,433
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates138$8,983
Sucralfate110$7,245
Lubiprostone39$4,361
Dexlansoprazole DrDexlansoprazole11$2,360
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg90$2,061
Dicyclomine Hcl62$1,316
Pantoprazole Sodium174$1,297
Colestipol Hcl23$1,228
Esomeprazole Magnesium12$952
Omeprazole88$740
Famotidine69$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$598$96,91795 claims
Aimmune Therapeutics, Inc.Zenpep$16$52,27213 claims
Phathom Pharmaceuticals, Inc.Voquezna$351$9,43311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Villa Rica

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →